Julie Eastland compensation by year
Zentalis Pharmaceuticals Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $94,231 | $700,000 |
| Bonus | $250,000 | $0 |
| Stock awards | $0 | $99,772 |
| Option awards | $7,791,824 | $56,975 |
| Non-equity incentive | $52,471 | $441,000 |
| Pension and deferred compensation | $0 | $0 |
| All other | $383 | $2,984 |
| Total | $8,188,909 | $1,300,731 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Zentalis Pharmaceuticals, Inc. DEF 14A filed April 30, 2026, accession 0001725160-26-000027, and prior-year filings.
How this page was built: the Zentalis Pharmaceuticals, Inc. filed document, accession 0001725160-26-000027. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 59,388 | $80,174 | — |
| Option | 47,016 | — | $1.68 |
| Option | 2,208,500 | — | $3.66 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Zentalis Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Zentalis Pharmaceuticals discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $1,050,000 | $20,043 | — | — |
| Resignation for good reason, no change in control | $1,050,000 | $20,043 | — | — |
| Change in control and resignation for good reason | $1,050,000 | $80,174 | — | — |
| Change in control and involuntary termination | $1,050,000 | $80,174 | — | — |
Per the Potential Payments Upon Termination or Change in Control table in Zentalis Pharmaceuticals, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Zentalis Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Andrea Paul | Former Chief Legal Officer and Corporate Secretary | $2,988,669 |
| Julie Eastland · this page | President and Chief Executive Officer | $1,300,731 |
| Mark Lackner | Former Chief Scientific Officer | $1,229,349 |
| Ingmar Bruns | Chief Medical Officer | $869,843 |
| James Bucher | Chief Legal Officer and Corporate Secretary | $659,973 |
Board service
Zentalis Pharmaceuticals board · FY2024–FY2025How this board is paid
Company policy: Zentalis Pharmaceuticals pays directors a $45,000 cash retainer. As stated in Zentalis Pharmaceuticals's FY2025 proxy.
The full Zentalis Pharmaceuticals compensation record
free company briefThis page is one person within Zentalis Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Zentalis Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Zentalis Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Zentalis Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.